Don't want ads? Subscribe or login now.

PepGen Faces Investor Suit Over Muscular Dystrophy Drug

By Sydney Price · June 11, 2025, 6:35 PM EDT

Clinical-stage biotech company PepGen Inc. has been hit with a proposed shareholder class action alleging it misled investors about the efficacy and commercial prospects of its muscular dystrophy drug, causing share...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Karam v. PepGen Inc. et al

Case Number

1:25-cv-03221

Court

New York Eastern

Nature of Suit

Securities/Commodities

Date Filed

June 09, 2025

Recent Articles By Sydney

October 10, 2025
ATyr Pharma Faces Investor Suit Over Failed Drug Trial
October 10, 2025
Pharma Co. Escapes Suit Over Ex-CEO's Alleged Misconduct
October 07, 2025
Biogen Says Investors Can't Expand Alzheimer's Drug Suit
September 26, 2025
Semler Scientific, Bard To Pay $37M To End FCA Claims
September 24, 2025
UnitedHealth Fights Investor Suit Over DOJ's Merger Probe
September 23, 2025
Axsome Settles Investors' Drug Approval Suit For $7.8M
September 10, 2025
DexCom Beats Most Of Investors' Diabetes Device Sales Suit
August 25, 2025
Healthcare Co. Investors Sue Over Contractor's Alleged Fraud
August 22, 2025
Rite Aid Execs Dodge Investor Suit Over Opioid Litigation
August 19, 2025
3D Systems Brass Sued Over Revenue Projections